Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma

Area of Science:

• Oncology
• Immunology
• Cell Therapy

Background:

• Advanced melanoma survival has improved with immune checkpoint inhibitors and targeted therapies.
• Patients with nonresponding or relapsing melanoma still face a poor prognosis.

Approach:

• This review discusses adoptive T-cell therapies for melanoma, including historical development, current status, and future directions.
• Tumor-infiltrating lymphocytes (TILs) can induce responses in up to 50% of patients with metastatic melanoma refractory to anti-programmed cell death 1 therapy.
• Genetically engineered T cells, such as those with chimeric antigen receptors (CARs) or engineered T-cell receptors (TCRs), are being explored.

Key Points:

• Adoptive cell therapy, particularly TILs, offers a promising treatment avenue for advanced melanoma patients unresponsive to standard therapies.
• Durable complete responses are achievable with TIL therapy, reaching up to 20% in refractory populations.
• Genetically modifying T cells represents a next-generation approach to enhance efficacy in difficult-to-treat melanoma.

Conclusions:

• Adoptive T-cell therapies are a significant advancement for advanced melanoma, especially for patients with limited options.
• Further research into genetically modified T-cell therapies holds potential for improved outcomes in refractory melanoma.
• The review highlights the evolving landscape and future potential of cell-based treatments in melanoma management.